592 related articles for article (PubMed ID: 20942789)
1. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
2. Altered Proteostasis in Neurodegenerative Tauopathies.
Papanikolopoulou K; Skoulakis EMC
Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
[TBL] [Abstract][Full Text] [Related]
3. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
4. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.
Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ
Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796
[TBL] [Abstract][Full Text] [Related]
5. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.
Stozicka Z; Zilka N; Novak P; Kovacech B; Bugos O; Novak M
J Neuroinflammation; 2010 Oct; 7():64. PubMed ID: 20937161
[TBL] [Abstract][Full Text] [Related]
6. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
Brandt R; Hundelt M; Shahani N
Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
[TBL] [Abstract][Full Text] [Related]
7. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
8. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
9. The ordered assembly of tau is the gain-of-toxic function that causes human tauopathies.
Goedert M
Alzheimers Dement; 2016 Oct; 12(10):1040-1050. PubMed ID: 27686274
[TBL] [Abstract][Full Text] [Related]
10. Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice.
Kambe T; Motoi Y; Inoue R; Kojima N; Tada N; Kimura T; Sahara N; Yamashita S; Mizoroki T; Takashima A; Shimada K; Ishiguro K; Mizuma H; Onoe H; Mizuno Y; Hattori N
Neurobiol Dis; 2011 Jun; 42(3):404-14. PubMed ID: 21324362
[TBL] [Abstract][Full Text] [Related]
11. Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration.
García-León JA; Cabrera-Socorro A; Eggermont K; Swijsen A; Terryn J; Fazal R; Nami F; Ordovás L; Quiles A; Lluis F; Serneels L; Wierda K; Sierksma A; Kreir M; Pestana F; Van Damme P; De Strooper B; Thorrez L; Ebneth A; Verfaillie CM
Alzheimers Dement; 2018 Oct; 14(10):1261-1280. PubMed ID: 30036493
[TBL] [Abstract][Full Text] [Related]
12. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
13. Tau aggregation is a therapeutic target for Alzheimer's disease.
Takashima A
Curr Alzheimer Res; 2010 Dec; 7(8):665-9. PubMed ID: 20678070
[TBL] [Abstract][Full Text] [Related]
14. Potential neuroprotective strategies against tauopathy.
Wheeler JM; Guthrie CR; Kraemer BC
Biochem Soc Trans; 2012 Aug; 40(4):656-60. PubMed ID: 22817711
[TBL] [Abstract][Full Text] [Related]
15. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
16. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
Helboe L; Egebjerg J; Barkholt P; Volbracht C
Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of tau-induced neurodegeneration.
Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
[TBL] [Abstract][Full Text] [Related]
18. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
19. Tau pathophysiology in neurodegeneration: a tangled issue.
Spires-Jones TL; Stoothoff WH; de Calignon A; Jones PB; Hyman BT
Trends Neurosci; 2009 Mar; 32(3):150-9. PubMed ID: 19162340
[TBL] [Abstract][Full Text] [Related]
20. Propagation of Tau Aggregates and Neurodegeneration.
Goedert M; Eisenberg DS; Crowther RA
Annu Rev Neurosci; 2017 Jul; 40():189-210. PubMed ID: 28772101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
